Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2007Diabetes Obesity and MetabolismOpen Access

HbA1c changes from baseline were -0.67% at Week 52 in both groups, confirming non-inferiority.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does sitagliptin reduce HbA1c non-inferiorly to glipizide in patients with type 2 diabetes inadequately controlled on metformin?

Population

1172 patients with type 2 diabetes and inadequate glycaemic control on metformin monotherapy.

Comparison

Sitagliptin 100 mg once daily added to metformin… vs Glipizide 5 mg/day added to metformin…

Design

RCT, randomized, double-blind

Follow-up

52 weeks

Authors

MNMichael A. NauckGMGary MeiningerLTLisa Terranella

Discussion

Loading...

Member takes

Overview

Sitagliptin provides a non-inferior glycemic option to glipizide in metformin-treated type 2 diabetes; confirms DPP-4 inhibitor viability versus sulfonylureas.

Structured PICO

Does sitagliptin reduce HbA1c non-inferiorly to glipizide in patients with type 2 diabetes inadequately controlled on metformin?

P
Population
1172 patients with type 2 diabetes and inadequate glycaemic control (HbA1c ≥ 6.5 and ≤ 10%) on metformin monotherapy (≥ 1500 mg/day).
I
Intervention
Sitagliptin 100 mg once daily added to metformin monotherapy for 52 weeks
C
Comparator
Glipizide 5 mg/day (uptitrated to a potential maximum 20 mg/day) added to metformin monotherapy for 52 weeks
O
Outcome
HbA1c changes from baseline at Week 52surrogate

Sitagliptin is non-inferior to glipizide for HbA1c lowering in type 2 diabetes inadequately controlled on metformin, but offers a lower risk of hypoglycemia and induces weight loss rather than weight gain.

Cite This Study

Nauck et al. (2007) studied this question.

synapsesocial.com/papers/6a7d08a1ade38b7dc346c9bchttps://doi.org/10.1111/j.1463-1326.2006.00704.x
View Full Paper
Ask AI
Bookmark
Share